South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

NEW ORLEANS, Oct. 12, 2023 . South Rampart Pharma, Inc. ( " South Rampart " or the " Company " ), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials